NCT03928314: Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Solid Tumors

NCT03928314
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated, unstable, symptomatic CNS metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03928314

Comments are closed.

Up ↑